Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (1995)
All Articles published online
|
Mar 1, 2004 (publication date) through Apr 24, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Nomura K, Matsumoto Y, Yoshida N, Taji S, Wakabayashi N, Mitsufuji S, Horiike S, Morita M, Okanoue T, Taniwaki M. Successful treatment with rifampin for fulminant antibiotics-associated colitis in a patient with non-Hodgkin’s lymphoma. World J Gastroenterol 2004; 10(5): 765-766 [PMID: 14991957 DOI: 10.3748/wjg.v10.i5.765] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v10/i5/765.htm |
| Number | Citing Articles |
| 1 |
Jihad Bishara, Yoram Bloch, Moshe Garty, Jaqueline Behor, Zmira Samra. Antimicrobial resistance of Clostridium difficile isolates in a tertiary medical center, Israel. Diagnostic Microbiology and Infectious Disease 2006; 54(2): 141 doi: 10.1016/j.diagmicrobio.2005.09.008
|
| 2 |
Nicola Petrosillo, Guido Granata, Maria Adriana Cataldo. Novel Antimicrobials for the Treatment of Clostridium difficile Infection. Frontiers in Medicine 2018; 5 doi: 10.3389/fmed.2018.00096
|
| 3 |
Kevin W Garey, Miguel Salazar, Dhara Shah, Richard Rodrigue, Herbert L DuPont. Rifamycin Antibiotics for Treatment of Clostridium difficile–Associated Diarrhea. Annals of Pharmacotherapy 2008; 42(6): 827 doi: 10.1345/aph.1K675
|
| 4 |
Rajaraman Durai. Epidemiology, Pathogenesis, and Management of Clostridium difficile Infection. Digestive Diseases and Sciences 2007; 52(11): 2958 doi: 10.1007/s10620-006-9626-y
|
| 5 |
Omar Abughanimeh, Ayman Qasrawi, Osama Kaddourah, Laith Al Momani, Mouhanna Abu Ghanimeh. Clostridium difficileinfection in oncology patients: epidemiology, pathophysiology, risk factors, diagnosis, and treatment. Hospital Practice 2018; 46(5): 266 doi: 10.1080/21548331.2018.1533673
|
| 6 |
Lynne V McFarland. Alternative treatments for Clostridium difficile disease: what really works?. Journal of Medical Microbiology 2005; 54(2): 101 doi: 10.1099/jmm.0.45753-0
|
| 7 |
F. Barbut, J.-L. Meynard, C. Eckert. Traitement des infections digestives à Clostridium difficile : anciennes et nouvelles approches. Journal des Anti-infectieux 2011; 13(2): 74 doi: 10.1016/j.antinf.2011.03.002
|
| 8 |
Harsh Mathur, Mary C Rea, Paul D Cotter, R Paul Ross, Colin Hill. The potential for emerging therapeutic options forClostridium difficileinfection. Gut Microbes 2014; 5(6): 696 doi: 10.4161/19490976.2014.983768
|
| 9 |
Dorothy Surowiec, Arpi G Kuyumjian, Michael A Wynd, Cristina E Cicogna. Past, Present, and Future Therapies for Clostridium difficile–Associated Disease. Annals of Pharmacotherapy 2006; 40(12): 2155 doi: 10.1345/aph.1H332
|
| 10 |
Muhammad Aziz, Rawish Fatima, Lindsey N. Douglass, Omar Abughanimeh, Shahzad Raza. Current updates in management of Clostridium difficile infection in cancer patients. Current Medical Research and Opinion 2019; 35(3): 473 doi: 10.1080/03007995.2018.1487389
|
| 11 |
Jennifer L. Cribb, Karly O'Brien, Christina E. DeRemer. Rifaximin in Combination with Metronidazole and Oral Vancomycin for the Treatment of an Initial Episode of Clostridium difficile–Associated Diarrhea: Case Report and Literature Review. Hospital Pharmacy 2012; 47(3): 206 doi: 10.1310/hpj4703-206
|
| 12 |
J. Stein, O. Schröder. Infektiologie des Gastrointestinaltraktes. 2006; : 265 doi: 10.1007/3-540-37211-3_34
|
| 13 |
Caitlin R. Musgrave, P. Brandon Bookstaver, S. Scott Sutton, April D. Miller. Use of alternative or adjuvant pharmacologic treatment strategies in the prevention and treatment of Clostridium difficile infection. International Journal of Infectious Diseases 2011; 15(7): e438 doi: 10.1016/j.ijid.2011.03.017
|